Gaudium Ivf And Women Health Limited
Minimum investment
Bidding date
20 Feb - 24 Feb 2026
Price range
₹75 - ₹79
Minimum quantity
189
Minimum investment
₹14,175
Issue size
₹165 Cr.
IPO doc (link)
RHP docs
Listing exchange
NSE/BSE
Category | Subscription |
|---|---|
Qualified Institutional Buyers | 0.93x |
Retail Individual Investor | 5.88x |
Non-Institutional Investor | 11.44x |
Others | - |
Total | 5.88x |
Gaudium IVF and Women Health Limited was incorporated in March 2015 and is engaged in providing assisted reproductive technology (ART) and fertility treatments across India. The company focuses on advanced In Vitro Fertilization (IVF) services and has expanded its presence in multiple states through a hub-and-spoke operating model. Currently, the company operates more than 30 locations, including 7 hub centres and 28 spoke centres. It has also entered into a strategic alliance with infertility experts to spread awareness about fertility and reproductive health treatments. Gaudium IVF serves both domestic and international patients from countries such as Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman. The company has centres in major cities like Delhi, Mumbai, Bangalore, Ludhiana, Srinagar, and Patna, which helps it cover key urban markets in India. The company offers a wide range of fertility and women’s health services such as IVF, ICSI, IUI, ovulation induction, PCOS and endometriosis treatment, and high-risk pregnancy care. It also provides advanced male infertility treatments, including sperm retrieval procedures.
Patient-Centric Approach: The company focuses on customized treatments and patient satisfaction, which helps build long-term relationships and referrals.
Strong Medical Team: Gaudium IVF has a team of experienced doctors and specialists in reproductive medicine.
Advanced Technology: Use of next-generation INTEGRA Ti labs for ICSI and advanced ultrasound-guided procedures enhances success rates.
Presence in Prime Urban Markets: The company has established central hubs in major cities such as Mumbai, Bangalore, Delhi NCR, and Patna.
High Operating Margins: The company maintains strong EBITDA and PAT margins, reflecting operational efficiency.
Highly Competitive Industry: The fertility treatment sector is competitive, with many established and regional players.
Regulatory Risks: The company operates in a regulated healthcare industry, and any changes in ART or healthcare policies can affect business.
Dependence on Skilled Professionals: The success of the company depends on experienced doctors and medical staff. Loss of key personnel may impact operations.
Geographic Concentration: Although expanding, a significant portion of revenue still comes from key urban centres.
High Valuation: The IPO valuation may appear expensive compared to peers, which could limit short-term listing gains.
49.75 Cr.
Sep'25
12.51 Cr.
Sep'25
18.95 Cr.
Sep'25
Active IPOs | |
|---|---|
Company name | Bid starts |
Adisoft Technologies | 23-04-2026 |
Amba Auto Sales And Services | 27-04-2026 |
